This generally well-conducted review concluded, although rates of death, stent thrombosis and restenosis were similar between patients undergoing bifurcation stenting with drug-eluting stents, myocardial infarction was more common with a two-stent strategy; provisional stenting should be the primary strategy. However, in the absence of a significant effect on mortality, the authors' conclusions and recommendations for practice may be overstated.
Study selection
Randomised controlled trials (RCTs) that compared provisional drug-eluting stent versus two drug-eluting stent strategies for the treatment of bifurcation stenoses in patients with coronary artery disease were eligible for inclusion. Trials had to report the rate of restenosis. Patients were allowed to receive clopidogrel treatment.
Outcomes were mortality, myocardial infarction, target lesion revascularisation, and stent thrombosis.
The included trials compared provisional sirolimus or paclitaxel drug-eluting stents versus sirolimus or paclitaxel drugeluting two-stent strategy for the treatment of bifurcation lesions. The mean age of included patients ranged from 60 to 67 years; most of the patients were male (77 to 81%). All patients received clopidogrel treatment for three to 12 months.
Two reviewers performed study selection.
Assessment of study quality
Quality assessment was conducted using a risk of bias table, which assessed sequence generation, allocation concealment, blinding, incomplete outcome data assessed, selective reporting, and other biases. Each quality item was scored as low risk of bias, unclear risk of bias, or high risk of bias.
The authors did not state how many reviewers performed the validity assessment.
Data extraction
Two reviewers independently extracted data on mortality, myocardial infarction, target lesion revascularisation, restenosis and thrombosis. Data were used to calculate relative risks (RRs) and 95% confidence intervals (CIs). Where possible, intention-to-treat data were used.
Methods of synthesis
The pooled relative risks were calculated using a Mantel-Haenszel fixed-effects meta-analysis, when no statistical heterogeneity was detected; a random-effect meta-analysis was used when statistical heterogeneity was detected. Statistical heterogeneity was assessed using the I 2 statistic and Cochrane Q test. The absolute risk difference (RD) and
Results of the review
Six RCTs were included in the review (n=1,641 patients). The sample size of the included trials ranged from 85 to 500 patients. Trial quality assessment indicated that for many quality factors there was a low risk of bias, but for blinding there was high to uncertain risk of bias.
Compared with the two drug-eluting stent strategy, provisional drug-eluting stenting had a statistically significant lower risk of myocardial infarction (RR 0.57, 95% CI 0.37 to 0.87; I 2 =13%), which equated to a pooled risk difference of -3.0% (95% CI -1.0% to -5.0%); the number needed to treat to prevent one myocardial infarction using the provisional strategy was 33 patients. There was no statistically significant difference between the two-stent strategy and the provisional strategy for mortality, target lesion revascularisation, main-branch stenosis, side-branch stenosis, or stent thrombosis.
Sensitivity analyses indicated that larger trials, multicentre studies, and longer follow-up periods were more likely to show an increase in myocardial infarction with the two-stent strategy.
There was no evidence of publication bias.
Authors' conclusions
The use of a one-stent strategy with provisional T-stenting of the side branch yielded similar rates of death, restenosis and stent thrombosis compared with a two-stent strategy; provisional drug-eluting T-stenting should be considered the primary strategy for bifurcation stenoses.
CRD commentary
Inclusion criteria for the review were clearly defined. Several relevant databases were searched for articles in any language. Publication bias assessed and was not detected. Study selection and data extraction were conducted in duplicate to attempt to minimise error and bias, but it was unclear if the same process was used for quality assessment.
Quality assessment was based on a simple checklist of trial biases, which may not give a true reflection of trial quality. Trials were pooled using a fixed-effects or random-effects meta-analysis, depending on the presence of statistical heterogeneity. Sensitivity analyses were undertaken, which was appropriate. The results of the review demonstrated only one real difference between the two treatment strategies, so the authors' conclusion that provisional stenting should be used as the primary strategy was not fully supported by the data.
The review was generally well conducted but, in the absence of a significant effect on mortality, the authors' conclusions and recommendations for practice may be overstated.
